首页> 外文期刊>In vivo. >Impressive Long-term Response with Pertuzumab and Trastuzumab in HER2-positive Breast Cancer with Brain Metastasis
【24h】

Impressive Long-term Response with Pertuzumab and Trastuzumab in HER2-positive Breast Cancer with Brain Metastasis

机译:帕妥珠单抗和曲妥珠单抗对HER2阳性脑转移性乳腺癌的长期疗效令人印象深刻

获取原文
           

摘要

This is a case report of a 40-year-old woman who, after conservative breast cancer treatment, developed a HER2 positive solitary brain metastasis in the left temporal lobe, without extracranial disease. She underwent surgery resection followed by stereotactic radiotherapy and, because of early brain progression, she was submitted to the first line therapy with pertuzumab, trastuzumab and weekly paclitaxel. After six months of treatment, a brain magnetic resonance imaging revealed a complete disappearance of brain recurrence, which persisted for more than 24 months.
机译:这是一名40岁女性的病例报告,该女性在接受保守的乳腺癌治疗后,在左侧颞叶发生了HER2阳性孤立性脑转移,而没有颅外疾病。她接受了手术切除,随后进行了立体定向放射疗法,并且由于大脑的早期发展,她被接受了帕妥珠单抗,曲妥珠单抗和每周紫杉醇的一线治疗。治疗六个月后,大脑磁共振成像显示大脑复发完全消失,持续了超过24个月。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号